

LPL		LINCOLN PHARMACEUTICALS LIMITED		LPL	
<p style="text-align: center;">Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060. CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-67778000, Fax: +91-79-6777 8062 Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com</p>					
Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2017					
PART-I				(Rs. In Lakhs)	
Sr. No.	Particulars	Consolidated		Standalone	
		Quarter Ended		Quarter Ended	
		30/06/2017 (Unaudited)	30/06/2016 (Unaudited)	30/06/2017 (Unaudited)	30/06/2016 (Unaudited)
A	REVENUE				
(a)	Revenue from Operations (Net of excise duty)	13,486.12	8,916.27	8,719.45	7,611.08
(b)	Other Income	284.24	353.96	255.74	344.21
A	Total Revenue (a+b)	13,770.36	9,270.23	8,975.19	7,955.29
B	EXPENSES				
(a)	Cost of Materials Consumed	1,810.51	1,807.57	1,255.03	1,388.08
(b)	Purchase of Stock-In-Trade	8,198.78	2,626.63	4,245.88	2,091.84
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	145.07	645.38	208.92	644.36
(d)	Employee Benefits Expense	1,117.37	1,263.23	1,050.22	1,148.99
(e)	Finance Cost	160.79	211.93	117.43	164.01
(f)	Depreciation and Amortisation Expense	138.00	138.11	96.00	96.11
(g)	Other Expenses	1,512.89	1,063.15	1,377.19	1,015.07
B	Total Expenses (a+g)	13,083.41	7,756.00	8,350.67	6,548.46
C	Profit before Exceptional and Extraordinary Items and Tax (A-B)	686.95	1,514.23	624.52	1,406.83
	Exceptional Items	0.00	0.00	0.00	0.00
D	Profit before Extraordinary Items and Tax	686.95	1,514.23	624.52	1,406.83
	Extraordinary items	0.00	0.00	0.00	0.00
E	Profit before Tax	686.95	1,514.23	624.52	1,406.83
F	Tax Expense	195.26	374.32	174.17	345.79
G	Profit before Other Comprehensive Income as per IND-AS	491.69	1,139.91	450.34	1,061.04
	Other Comprehensive Income	-1.49	1.52	-1.55	1.42
H	Profit for the period after Other Comprehensive Income as per IND-AS	490.20	1,141.43	448.79	1,062.46
	Share of Profit of Minority	0.65	1.11	0.00	0.00
I	Profit for the period after Minority Interest	489.55	1,140.32	448.79	1,062.46
J	Paid-up equity share capital of face value Rs.10/- each	2,000.00	1,631.80	2,000.00	1,631.80
K	Reserve Excluding Revaluation Reserves	17,520.56	-----	17,115.78	-----
L	Earnings Per Equity Share (Not Annualised)				
(a)	Basic	2.45	6.99	2.24	6.51
(b)	Diluted	2.45	6.99	2.24	6.51
NOTES:					
1	The Financial Results of the Company for the Quarter Ended June 30, 2017 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on September 14, 2017. The Statutory Auditors of the Company have carried out Limited Review of these Results and the Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.				
2	The Company adopted Indian Accounting Standards (IND-AS) from April 1, 2017 and accordingly these Financial Results have been prepared in accordance with the recognition and measurement principles laid down in the IND-AS 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Financial for the Quarter have been prepared in accordance with the recognition and measurement principles of IND-AS 34.				
3	The Format for Un-Audited Quarterly Results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular CIR/CFD/FAC/62/2016 dated July 5, 2016, IND-AS and Schedule III (Division II) to the Companies Act, 2013 applicable to Companies that are required to Company with IND-AS.				
4	The Statement does not include IND-AS compliant Results for the preceding Quarter and the Previous Year Ended March 31, 2017 as the same is not mandatory as per SEBI Circular CIR/CFD/FAC/62/2016 dated July 5, 2016.				
5	Consequent to transition from the previous IGAAP to IND-AS, the Reconciliation of Profit / (Loss) for the Quarter Ended June 30, 2016 is provided below in accordance with the requirements of Paragraph 32 of IND-AS 101, "First Time Adoption of IND-AS".				
	Particulars			Quarter Ended on June 30, 2016	
	Net Profit/Reserves as per IGAAP			1,015.49	
	Add / (Less): Adjustments for GAAP Differences				
	Effect of measuring investments at fair value through Profit and Loss			0.00	
	Effect of measuring Loan to Employee at Fair Value through Profit and Loss			-1.99	
	Actuarial Gain / Loss on Employee defined benefit plan recognized in Other Comprehensive Income			-1.42	
	Borrowings measured at Amortised Cost & Effect on Finance Cost			-0.89	
	Effect of measuring Lease Liability on Leasehold Land			0.00	
	Deferred Tax adjustments			-12.48	
	Others-Change in Accounting Policy			62.33	
	Net Profit before Other Comprehensive Income as per IND-AS			1,061.04	
6	Segment Reporting as defined in IND-AS 108 is not applicable, since the Company does not have any Operating Income.				
7	The IND-AS compliant corresponding figures in the previous year have not been subject to review/audit. However, the Company's Management has exercised necessary Due Diligence to ensure that such Financial Results provide a true and fair view of its affairs.				
8	Comparative figures have been re-arranged / re-grouped wherever necessary.				
9	Consolidated Results includes Results of its Subsidiaries.				
FOR LINCOLN PHARMACEUTICALS LIMITED					
PLACE: AHMEDABAD DATE: SEPTEMBER 14, 2017			MAHENDRA G. PATEL MANAGING DIRECTOR [DIN: 00104706]		